首页 > 抗体蛋白 > 抗体
PerCP anti-mouse CD3ε Antibody
产品名称:
PerCP anti-mouse CD3ε Antibody
产品类别:
抗体
产品编号:
100325
产品应用:
100325
[价格]
规格 价格 库存
25µg ¥ 1056 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD3ε antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, ?and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. K?nnecke I, et al. 2014. Bone. 64c:155. PubMed
  2. Cabrera-Mora M, et al. 2016. J Immunol. 197: 2748 - 2761. PubMed
  3. Li P, et al. 2020. J Cell Mol Med. 24:10151. PubMed
  4. Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed
  5. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  6. AbuEid M, et al. 2021. iScience. 24(6):102653. PubMed
  7. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  8. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  9. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  10. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  11. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  12. Fasbender F, et al. 2017. Front Immunol. 0.88125. PubMed
  13. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  14. Neumann AM et al. 2017. PloS one. 12(11):e0187330 . PubMed
  15. Xie X, et al. 2010. Proc Natl Acad Sci U S A. 107:8754. PubMed
  16. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  17. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
  18. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  19. Markov SD, et al. 2021. Mol Cancer Ther. 20:2457. PubMed
  20. Ma YS, et al. 2021. Mol Ther Oncolytics. 484:20. PubMed
  21. Cha H, et al. 2010. J Immunol. 184:6799. PubMed
  22. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  23. Pérez-Girón J, et al. 2015. J Vis Exp. 100: 52803. PubMed
  24. Chang J, et al. 2010. PLoS One. 5:e12925. PubMed
  25. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
  26. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  27. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  28. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  29. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
  30. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  31. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  32. Li Z, et al. 2020. Front Cell Dev Biol. 8:572689. PubMed
  33. Terp MG, et al. 2021. Mol Oncol. 15:3299. PubMed
  34. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  35. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  36. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  37. Stack G, et al. 2015. PLoS Pathog. 11:1004641. PubMed
  38. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  39. Arima Y et al. 2017. eLife. 6 pii: e25517. PubMed
RRID
AB_893319 (BioLegend Cat. No. 100325) AB_893317 (BioLegend Cat. No. 100326)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线